# Tango Therapeutics

Source: https://onco.cc/companies/tango-therapeutics/  
OnCo record `tango-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Tango Therapeutics makes cancer pills that exploit a weakness created when a tumour loses a particular gene. Its lead drug targets cancers that have lost a gene called MTAP, common in pancreatic and lung cancer.

## Summary

Tango Therapeutics is a Boston precision oncology company built on synthetic lethality: it uses CRISPR-based functional genomic screens to find targets that cancer cells depend on once they have lost a tumour suppressor gene. Its lead programme, vopimetostat (TNG462), is an MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers, listed in phase 1/2 and phase 3 development in pancreatic, lung and other non-CNS cancers, with a phase 1/2 combination study alongside Revolution Medicines' RAS inhibitors. TNG456, a brain-penetrant PRMT5 inhibitor, is in phase 1/2 for MTAP-deleted glioblastoma. All programmes are wholly owned. Tango listed on Nasdaq in August 2021 through a merger with BCTG Acquisition Corp, a SPAC sponsored by Boxer Capital, with a 186 million US dollar PIPE and about 353 million US dollars in expected total proceeds; Gilead Sciences was an existing shareholder.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Boston, MA
- Type: biotech
- Website: https://www.tangotx.com/
- Ticker: TNGX

## Notes

- Founding year (2017) not sourced from a fetched page. Final proceeds after redemptions were not confirmed; the 353 million figure is the expected total stated in the announcement.

## Sources

- Official website: https://www.tangotx.com/
- Pipeline: https://www.tangotx.com/pipeline/
- BCTG merger announcement (SEC exhibit): https://www.sec.gov/Archives/edgar/data/1819133/000121390021021456/ea139433ex99-1_bctgacq.htm

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [CRISPR functional genomics](https://onco.cc/technologies/crispr-screens/), [Synthetic lethality approaches](https://onco.cc/technologies/synthetic-lethality-approaches/)
- drugs: [TNG260](https://onco.cc/drugs/tng260/), [TNG456](https://onco.cc/drugs/tng456/), [TNG462](https://onco.cc/drugs/tng462/)
- trials: [S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP](https://onco.cc/trials/nct06188702/), [Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss](https://onco.cc/trials/nct06810544/), [Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors](https://onco.cc/trials/nct05732831/), [Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors](https://onco.cc/trials/nct05887492/), [Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients](https://onco.cc/trials/nct06922591/)
- companies: [Bain Capital Life Sciences](https://onco.cc/companies/bain-capital-life-sciences/), [Boxer Capital](https://onco.cc/companies/boxer-capital/), [Casdin Capital](https://onco.cc/companies/casdin-capital/), [Cormorant Asset Management](https://onco.cc/companies/cormorant-asset-management/), [EcoR1 Capital](https://onco.cc/companies/ecor1-capital/), [Foresite Capital](https://onco.cc/companies/foresite-capital/), [Logos Capital](https://onco.cc/companies/logos-capital/), [RA Capital Management](https://onco.cc/companies/ra-capital/), [Samsara BioCapital](https://onco.cc/companies/samsara-biocapital/)

---
JSON: https://onco.cc/api/v1/entities/tango-therapeutics.json